

Konstantin Mechler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577855/publications.pdf>

Version: 2024-02-01

29
papers

362
citations

933410

10
h-index

940516

16
g-index

31
all docs

31
docs citations

31
times ranked

465
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | Evidence-based pharmacological treatment options for ADHD in children and adolescents. , 2022, 230, 107940. | | 68 |
| 2 | Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. <i>Genetics in Medicine</i> , 2015, 17, 965-970. | 2.4 | 45 |
| 3 | Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 46. | 2.7 | 40 |
| 4 | Non-adherence to Psychotropic Medication Among Adolescents – A Systematic Review of the Literature. <i>Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2018, 46, 69-78. | 0.7 | 30 |
| 5 | Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 141. | 1.6 | 23 |
| 6 | FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis. <i>PLoS ONE</i> , 2020, 15, e0230898. | 2.5 | 17 |
| 7 | Quantitative retrospective natural history modeling for orphan drug development. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 99-109. | 3.6 | 16 |
| 8 | Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature. <i>Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2018, 46, 246-263. | 0.7 | 16 |
| 9 | Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). <i>BMC Psychiatry</i> , 2018, 18, 327. | 2.6 | 15 |
| 10 | Critical appraisal of genotype assessment in molybdenum cofactor deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 801-811. | 3.6 | 13 |
| 11 | Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished – a cross-sectional analysis. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, . | 2.1 | 13 |
| 12 | Disasters in Germany and France: An Analysis of the Emergency Events Database From a Pediatric Perspective. <i>Disaster Medicine and Public Health Preparedness</i> , 2019, 13, 958-965. | 1.3 | 11 |
| 13 | Patterns of extreme temperature-related catastrophic events in Europe including the Russian Federation: a cross-sectional analysis of the Emergency Events Database. <i>BMJ Open</i> , 2021, 11, e046359. | 1.9 | 9 |
| 14 | “When I Stop My Medication, Everything Goes Wrong” Content Analysis of Interviews with Adolescent Patients Treated with Psychotropic Medication. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 655-662. | 1.3 | 7 |
| 15 | Structural and functional MRI of altered brain development in a novel adolescent rat model of quinpirole-induced compulsive checking behavior. <i>European Neuropsychopharmacology</i> , 2020, 33, 58-70. | 0.7 | 7 |
| 16 | Medication Adherence in Adolescents with Psychiatric Disorders. <i>Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie</i> , 2021, 49, 295-306. | 0.7 | 5 |
| 17 | Screening for ADHD-Related Symptoms in Preschoolers Should Be Considered – Results From a Representative Sample of 5-Year-Olds From a German Metropolitan Region. <i>Frontiers in Psychiatry</i> , 2018, 9, 612. | 2.6 | 4 |
| 18 | “Include me if you can” reasons for low enrollment of pediatric patients in a psychopharmacological trial. <i>Trials</i> , 2021, 22, 178. | 1.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | “Drugs Don’t Work in Patients Who Don’t Take Them”, Zeitschrift Für Kinder- Und Jugendpsychiatrie Und Psychotherapie, 2019, 47, 528-534. | 0.7 | 4 |
| 20 | Actigraphy-Derived Sleep Profiles of Children with and without Attention-Deficit/Hyperactivity Disorder (ADHD) over Two Weeks” Comparison, Precursor Symptoms, and the Chronotype. Brain Sciences, 2021, 11, 1564. | 2.3 | 4 |
| 21 | Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.”- a cross-sectional analysis. BMC Medical Ethics, 2020, 21, 20. | 2.4 | 3 |
| 22 | Intuitive Global Insight Into COVID-19 Clinical Research Activities”The “COVID-19 Map of Hope”, Journal of Clinical Pharmacology, 2020, 60, 826-827. | 2.0 | 3 |
| 23 | Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior. Psychopharmacology, 2022, 239, 2457-2470. | 3.1 | 2 |
| 24 | Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders. Molecular and Cellular Pediatrics, 2015, 2, A1. | 1.8 | 1 |
| 25 | Natural History of Molybdenum Cofactor Deficiency. Neuropediatrics, 2014, 45, . | 0.6 | 0 |
| 26 | FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898. | | 0 |
| 27 | FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898. | | 0 |
| 28 | FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898. | | 0 |
| 29 | FDA orphan drug designations for lysosomal storage disorders “ a cross-sectional analysis. , 2020, 15, e0230898. | | 0 |